News und Analysen

• AI Power Crunch: Why Bloom Energy Is the Hidden Winner

Plug Power (NASDAQ:PLUG) reported higher first-quarter revenue and a narrower gross loss as management said cost cuts, stronger electrolyzer

American Public Education (NASDAQ:APEI) reported higher first-quarter 2026 revenue and profitability, raised its full-year outlook and said its newly reorganized business structure is beginning to

• 3 Stocks That Could Be Next to Announce a Stock Split

McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its

Lincoln National (NYSE:LNC) reported a seventh consecutive quarter of year-over-year adjusted operating income growth, with management pointing to stronger underwriting results, spread income

Ingredion (NYSE:INGR) reported a weaker-than-expected first quarter of 2026, as operational problems at its Argo facility weighed heavily on results in its Food & Industrial Ingredients U.S. Canada

• These 5 stocks have unique competitive edge and room to run

International Flavors & Fragrances (NYSE:IFF) reported a stronger-than-expected start to 2026, with first-quarter sales growth across all

• 3 Small Caps That Have Big Upside

Herbalife (NYSE:HLF) reported first-quarter 2026 results above its prior guidance, citing continued momentum in several international markets and progress on its

• Genworth Financial Stock is Retracing Fine

Genworth Financial (NYSE:GNW) reported first-quarter 2026 net income of $47 million and adjusted operating income excluding its Closed Block segment of

• Sportradar Rides the Sports Betting Trend From Behind the Curtain

Genius Sports (NYSE:GENI) reported what management described as another quarter of balanced growth, with first-quarter 2026 group

• Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish

FrontView REIT (NYSE:FVR) reported a stronger first quarter and raised its full-year AFFO per share outlook, as management

AptarGroup (NYSE:ATR) used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance

Cooper-Standard (NYSE:CPS) reported higher first-quarter sales and improved gross margin, while management said the auto supplier remains on track to meet or exceed its full-year targets despite

• 3 Beauty Stocks Off to an Ugly Start—Can 1 Stage a Comeback?

Coty (NYSE:COTY) executives said the beauty company is working to narrow the gap between retail sell-out and sell-in, sharpen its

Compass Minerals International (NYSE:CMP) reported improved profitability in its fiscal second quarter despite lower revenue, as management pointed to stronger margins, progress in its Plant

Compania Cervecerias Unidas (NYSE:CCU) began 2026 with strong results in its Chile business, but softness in Argentina and a sharp downturn in wine weighed on consolidated performance, Chief

• 2026 Sector Playbook: 3 Sectors Trading Below Fair Value

Algonquin Power & Utilities (NYSE:AQN) reported lower first-quarter 2026 earnings than a year earlier, while management said the company

• Caesars Surges on Buyout Buzz. Should Investors Take the Bet?

Wynn Resorts (NASDAQ:WYNN) executives said the casino operator delivered strong first-quarter results across Las Vegas and Macau while

• Is 2026 The Year to Load Up on Crypto Miners?

TeraWulf (NASDAQ:WULF) said its first-quarter 2026 results reflected a business shifting from Bitcoin mining toward contracted high-performance

• Silvaco Stock: Consider Early Investment in New Semiconductor

Service Properties Trust (NASDAQ:SVC) reported first-quarter 2026 results that management said reflected progress on a broader

Starz Entertainment (NASDAQ:STRZ) executives said the company delivered a strong first quarter of fiscal 2026 and is moving faster than previously expected toward its long-term margin target, aided

enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk